Cargando…
A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection among all infants worldwide and remains a significant cause of morbidity and mortality. To address this unmet medical need, MK‐1654, a half‐life extended RSV neutralizing monoclonal antibody, is in clinical d...
Autores principales: | Orito, Yuji, Otani, Naoyuki, Matsumoto, Yuki, Fujimoto, Katsukuni, Oshima, Nobuyuki, Maas, Brian M., Caro, Luzelena, Aliprantis, Antonios O., Cox, Kara S., Tokumaru, Osamu, Kodama, Masaaki, Kudo, Hideo, Imai, Hiromitsu, Uemura, Naoto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283748/ https://www.ncbi.nlm.nih.gov/pubmed/35506164 http://dx.doi.org/10.1111/cts.13290 |
Ejemplares similares
-
1384. RSV Monoclonal Antibody (MK-1654) Phase 1 Pharmacokinetics (PK) in Healthy Adults and Population PK Modeling to Support Pediatric Development
por: Maas, Brian, et al.
Publicado: (2018) -
1971. A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of a Respiratory Syncytial Virus (RSV) Neutralizing Monoclonal Antibody (MK-1654) in Healthy Subjects
por: Aliprantis, Antonios, et al.
Publicado: (2018) -
998. Forward and Reverse Translational Approaches to Predict Efficacy of the Neutralizing Respiratory Syncytial Virus (RSV) Antibody MK-1654
por: Maas, Brian M, et al.
Publicado: (2021) -
Curious Case of Hermaphroditism in 1654
Publicado: (1867) -
Evidence for dark matter in MG1654+134
por: Kochanek, C S
Publicado: (1994)